期刊文献+

慢性淋巴细胞白血病化疗过程中并发利妥昔单抗相关肺疾病一例并文献复习 被引量:1

原文传递
导出
摘要 目的 探讨利妥昔单抗相关肺疾病的临床特点、诊断及治疗.方法 回顾性分析1例慢性淋巴细胞白血病(CLL)化疗过程中并发利妥昔单抗相关肺疾病患者的临床资料,并复习相关文献.结果 该例CLL患者在利妥昔单抗联合冲击剂量甲泼尼龙治疗后第11天发生利妥昔单抗相关肺疾病,以发热、呼吸困难、双肺弥漫性毛玻璃样变为主要表现,对大剂量激素治疗反应良好.结论 利妥昔单抗相关肺疾病是利妥昔单抗应用中较为严重的并发症,可能导致患者死亡,当患者出现呼吸道症状或出现肺部影像学改变时需警惕该病.
出处 《白血病.淋巴瘤》 CAS 2014年第12期749-751,共3页 Journal of Leukemia & Lymphoma
  • 相关文献

参考文献19

  • 1Pfreundschuh M,Trumper L,Osterborg A,et al.CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:a randomised controlled trial by the MabThera International Trial (MInT) Group[J].Lancet Oncol,2006,7:379-391.
  • 2孙道萍,徐卫,李建勇.利妥昔单抗在造血干细胞移植治疗淋巴瘤中应用的研究进展[J].白血病.淋巴瘤,2014,23(8):503-506. 被引量:2
  • 3程婷婷,钟美佐,刘巍.利妥昔单抗联合化疗治疗非霍奇金淋巴瘤19例[J].白血病.淋巴瘤,2012,21(3):175-177. 被引量:6
  • 4Tony HP,Burmester G,Schulze-Koops H,et al.Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases:experience from a national registry (GRAID)[J].Arthritis Res Ther,2011,13:R75.
  • 5Patel VL,Mahevas M,Lee SY,et al.Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia[J].Blood,2012,119:5989-5995.
  • 6Kimby E.Tolerability and safety of rituximab (MabThera)[J].Cancer Treat Rev,2005,3 1:456-473.
  • 7Yang B,Lu XC,Yu RL,et al.Diagnosis and treatment of rituximab-induced acute tumor lysis syndrome in patients with diffuse large B-cell lymphoma[J].Am J Med Sci,2012,343:337-341.
  • 8Kasi PM,Tawbi HA,Oddis CV,et al.Clinical review:serious adverse events associated with the use of rituximab-a critical care perspective[J].Crit Care,2012,16:231.
  • 9Liote H,Liote F,Seroussi B,et al.Rituximab-induced lung disease:a systematic literature review[J].Eur Respir J,2010,35:681-687.
  • 10Hadjinicolaou AV,Nisar MK,Parfrey H,et al.Non-infectious pulmonary toxicity of rituximab:a systematic review[J].Rheumatology,2012,51:653-662.

二级参考文献53

  • 1秦铁军,邹德慧,王迎,赵耀中,李睿,孙晓明,王玫,钱林生,邱录贵.利妥昔单抗净化动员B细胞非霍奇金淋巴瘤外周血干细胞的初步研究[J].白血病.淋巴瘤,2006,15(6):430-432. 被引量:1
  • 2Weiner GJ.Rituximab:mechanism of action[J].Semin Hematol,2010,47:115-123.
  • 3Vellenga E,van Putten WL,van 't Veer MB,et al.Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL:a prospective randomized HOVON trial[J].Blood,2008,111:537-543.
  • 4Fenske TS,Hari PN,Carreras J,et al.Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma[J].Biol Blood Marrow Transplant,2009,15:1455-1464.
  • 5Gisselbrecht C,Glass B,Mounier N,et al.Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era[J].J Clin Oncol,2010,28:4184-4190.
  • 6Arcaini L,Montanari F,Alessandrino EP,et al.Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma[J].Ann Oncol,2008,19:1331-1335.
  • 7Kamezaki K,Kikushige Y,Numata A,et al.Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma[J].Bone Marrow Transplant,2007,39:523-527.
  • 8Kim MK,Kim S,Lee SS,et al.Rituximab-ESHAP as a mobilization regimen for relapsed or refractory B-cell lymphomas:a comparison with ESHAP[J].Transfusion,2007,47:1447-1454.
  • 9Horwitz SM,Negrin RS,Blume KG,et al.Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma[J].Blood,2004,103:777-783.
  • 10Khouri IF,Saliba RM,Hosing C,et al.Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas[J].J Clin Oncol,2005,23:2240-2247.

共引文献9

同被引文献1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部